Last reviewed · How we verify
NCT07143617
Exploratory Clinical Study on the Safety of STR-P004
NA trial testing STR-P004 in Autoimmune Diseases in 39 participants. Currently enrolling.
15 August 2026
Quick facts
| Lead sponsor | Beijing GoBroad Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 39 |
| Start date | 16 September 2025 |
| Primary completion | 15 August 2026 |
| Estimated completion | 14 September 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- STR-P004 — full drug profile →
Conditions studied
- Autoimmune Diseases — all drugs for Autoimmune Diseases →
Sponsor
Beijing GoBroad Hospital
Who can join
18 and older, any sex, with Autoimmune Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, multiple-dose escalation IIT clinical study aimed at evaluating the safety, tolerability, PK, and preliminary efficacy of STR-P004 in adult patients with relapsed or refractory autoimmune diseases.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of <i>in vivo</i> CAR-T platforms.
He L, Sun Y, Ma B, Lang G, et al · · 2026 · PMID 42093990 · DOI 10.3389/fimmu.2026.1772428
Verify or expand the search:
- PubMed search for NCT07143617
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of STR-P004
Trials testing the same drug.
- NCT07245251 — To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004 · NA · not yet recruiting
Other recruiting trials for Autoimmune Diseases
Currently open trials in the same condition.
- NCT06948110 — Deciphering the Genetic Architecture of Autoimmune Diseases · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07408336 — Clinical Study of AFN50 Injection in the Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07283315 — Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paedia · EARLY_PHASE1 · recruiting
- NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting
Other Beijing GoBroad Hospital trials
Trials by the same sponsor.
- NCT07520357 — A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinom · Phase 2 · not yet recruiting
- NCT06947473 — Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. · Phase 1, PHASE2 · recruiting
- NCT06326008 — Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri · Phase 1 · recruiting
- NCT07242417 — TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07179484 — To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07143617 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing GoBroad Hospital
- Last refreshed: 9 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07143617.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing